Zacks: Analysts Anticipate Spero Therapeutics Inc (NASDAQ:SPRO) Will Announce Earnings of -$0.89 Per Share

Equities research analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to post ($0.89) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Spero Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.87) and the lowest estimate coming in at ($0.92). Spero Therapeutics posted earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 48.3%. The business is scheduled to report its next earnings report on Thursday, November 14th.

On average, analysts expect that Spero Therapeutics will report full-year earnings of ($2.94) per share for the current fiscal year, with EPS estimates ranging from ($3.55) to ($2.12). For the next year, analysts expect that the company will post earnings of ($3.42) per share, with EPS estimates ranging from ($4.11) to ($2.82). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $6.95 million. Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%.



Several research analysts recently issued reports on the stock. TheStreet lowered shares of Spero Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 29th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Spero Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $20.60.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Spero Therapeutics by 56.0% during the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock valued at $7,559,000 after buying an additional 235,691 shares during the period. AWM Investment Company Inc. boosted its position in Spero Therapeutics by 6.4% during the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock valued at $6,887,000 after buying an additional 36,019 shares during the period. Novo Holdings A S purchased a new stake in Spero Therapeutics during the second quarter valued at about $5,363,000. Vanguard Group Inc. boosted its position in Spero Therapeutics by 4.5% during the second quarter. Vanguard Group Inc. now owns 437,204 shares of the company’s stock valued at $5,032,000 after buying an additional 18,814 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Spero Therapeutics by 89.7% during the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock valued at $2,474,000 after buying an additional 101,600 shares during the period. Institutional investors and hedge funds own 45.08% of the company’s stock.

Shares of SPRO traded up $0.22 during mid-day trading on Thursday, reaching $10.00. 4,147 shares of the stock traded hands, compared to its average volume of 30,021. The firm has a fifty day moving average price of $10.29 and a 200 day moving average price of $11.52. The company has a market cap of $182.50 million, a price-to-earnings ratio of -3.85 and a beta of 2.08. The company has a current ratio of 13.66, a quick ratio of 13.66 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Read More: Candlestick

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.